International Journal of Psychology & Behavior Analysis Volume 3 (2017), Article ID 3:IJPBA-121, 14 pages
Review Article
A Risk-Benefit Analysis of Antipsychotic Medication and Contingent Skin Shock for the Treatment of Destructive Behaviors

Nathan A. Blenkush

The Judge Rotenberg Center, 250 Turnpike Street, Canton, MA 02021, USA
Dr. Nathan Blenkush, The Judge Rotenberg Center, 250 Turnpike Street, Canton, MA 02021, USA; E-mail:
17 November 2016; 06 February 2017; 08 February 2017
Blenkush N (2017) A Risk-Benefit Analysis of Antipsychotic Medication and Contingent Skin Shock for the Treatment of Destructive Behaviors. Int J Psychol Behav Anal 3: 121. doi:


  1. Matson JL, LoVullo (2008) A review of Behavioral Treatments for Self- Injurious Behaviors of Persons with Autism Spectrum Disorders. Behav Modif 32: 61-76 [CrossRef] [Google Scholar] [PubMed]
  2. Wachtel LE, Hagopian LP (2006) Psychopharmacology and applied behavioral analysis: Tandem treatment of severe problem behaviors in intellectual disability and a case series. Isr J Psychiatry Relat Sci 43: 265- 274 [Google Scholar] [PubMed]
  3. Israel ML, Blenkush NA, von Heyn RE, Rivera PM (2008) Treatment of aggression with behavioral programming that includes supplementary skinshock. The Journal of Behavior Analysis of Offender and Victim Treatment and Prevention 1: 119-166 [CrossRef] [Google Scholar]
  4. Meinhold PM, Mulick JA (1992) Social policy and science in the treatment of severe behavior disorders: Defining and securing a healthy relationship. Clinical Psychology Review 12: 585-603 [CrossRef] [Google Scholar]
  5. Mikkelsen E (2007) The rationale use of psychotropic medication for individuals with intellectual disabilities. Kingston, NY: NADD Press
  6. Tiger JH, Hanley GP, Bruzek J (2008) Functional communication training: a review and practical guide. Behav Anal Pract 1: 16-23 [CrossRef] [Google Scholar] [PubMed]
  7. Chowdhury M, Benson BA (2011) Use of differential reinforcement to reduce behavior problems in adults with intellectual disabilities: a methodological review. Res Dev Disabil 32: 383-94 [CrossRef] [Google Scholar] [PubMed]
  8. Carr JE, Severtson JM, Lepper TL (2009) Noncontingent reinforcement is an empirically supported treatment for problem behavior exhibited by individuals with developmental disabilities. Res Dev Disabil 30: 44-57 [CrossRef] [Google Scholar] [PubMed]
  9. Smith RG, Iwata BA (1997) Antecedent influences on behavior disorders. J Appl Behav Anal 30: 343-375 [CrossRef] [Google Scholar] [PubMed]
  10. Lerman DC, Iwata BA, Wallace MD (1999) Side effects of extinction: prevalence of bursting and aggression during the treatment of self-injurious behavior. J Appl Behav Anal 32: 1-8 [CrossRef] [Google Scholar] [PubMed]
  11. Hanley GP, Iwata BA, McCord BE (2003) Functional analysis of problem behavior: a review. J Appl Behav Anal 36: 147-185 [CrossRef] [Google Scholar] [PubMed]
  12. Iwata BA, Dorsey MF, Slifer KJ, Bauman KE, Richman GS (1994) Toward a functional analysis of self-injury. J Appl Behav Anal 27: 197-209 [CrossRef] [Google Scholar] [PubMed]
  13. Mpakopoulou M, Gatos H, Brotis A, Paterakis KN, Fountas KN (2008) Stereotactic amygdalotomy in the management of severe aggressive behavioral disorders. Neurosurg Focus 25: E6 [CrossRef] [Google Scholar] [PubMed]
  14. Wachtel LE, Contrucci-Kuhn SA, Griffin M, Thompson A, Dhossche DM, et al. (2009) ECT for self-injury in an autistic boy. Eur Child Adolesc Psychiatry 18: 458-463 [CrossRef] [Google Scholar] [PubMed]
  15. Foxx RM (2004) The national institutes of health consensus development conference on the treatment of destructive behaviors: A study in professional politics. In J.W. Jacobson, R.M. Foxx, & J.A. Mulick (Eds.), Controversial Therapies for Developmental Disabilities Mahwah, NJ: Lawrence Erlbaum Associates, Inc. 461-476 p
  16. Marder SR, van Kammen DP (2005) Dopamine receptor antagonists (typical antipsychotics). In B.J. Sadock & V.A. Sadock (Eds.), Comprehensive Textbook of Psychiatry. Philadelphia, PA: Lippincott Williams & Wilkins. 2817-2838 p
  17. Aronson JK (Ed.) (2009) Meyler’s Side Effects of Psychiatric Drugs. Amsterdam: Elsevier [Google Scholar]
  18. Casey DE (1990) Tardive dyskinesia. West J Med 153: 535-541 [PubMed]
  19. Tarsy D, Lungu C, Baldessarini RJ (2011) Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handb Clin Neurol 100: 601-616 [CrossRef] [Google Scholar] [PubMed]
  20. Tamminga CA, Woerner MG (2002) Clinical course and cellular pathology of tardive dyskinesia. In Davis, Charney, Coyle, & Nemeroff (Eds.), Neuropsychopharmacology: The Fifth Generation of Progress. (pp. 1831- 1841). Philadelphia, PA: Lippincott Williams & Wilkins [Google Scholar]
  21. Rosenheck RA. (2007) Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics. Br J Psychiatry 191: 238-245 [CrossRef] [Google Scholar] [PubMed]
  22. Levenson JL (1985) Neuroleptic malignant syndrome. Am J Psychiatry 142: 1137-1145 [CrossRef] [Google Scholar] [PubMed]
  23. Adnet P, Lestavel P, Krivosic-Horber R (2000) Neuroleptic malignant syndrome. Br J Anaesth 85: 129-135 [CrossRef] [Google Scholar] [PubMed]
  24. Allison DB, Mentore JL, Moonseong H, Chandler LP, Capelleri JC, et al. (1999) Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 156: 1686-1696 [CrossRef] [Google Scholar] [PubMed]
  25. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M (2011) Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 378: 815-825 [CrossRef] [Google Scholar] [PubMed]
  26. Serretti A, Chiesa A (2011) A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol 26: 130-140 [CrossRef] [Google Scholar] [PubMed]
  27. Alldredge BK (1999) Seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations. Neurology 53: S68-75 [Google Scholar] [PubMed]
  28. Logothetis J (1967) Spontaneous epileptic seizures and electroencephalographic changes in the course of phenothiazine therapy. Neurology 17: 869-879 [CrossRef] [Google Scholar] [PubMed]
  29. PAUIG PM, DELUCA MA, OSTERHELD RG (1961) Thioridazine hydrochloride in the treatment of behavior disorders in epileptics. Am J Psychiatry 117: 832-833 [CrossRef] [Google Scholar] [PubMed]
  30. Rosenbloom AL (2010) Hyperprlactinemia with antipsychotic drugs in children and adolescents. Int J Pediatr Endocrinol 2010: 2010 [CrossRef] [Google Scholar] [PubMed]
  31. Madhusoodanan S, Parida S, Jimenez C (2010) Hyperprolactinemia associated with psychotropics--a review. Hum Psychopharmacol 25: 281- 297 [CrossRef] [Google Scholar] [PubMed]
  32. Crawford AM, Beasley CM, Tollefson (1997) The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 26: 41-54 [CrossRef] [Google Scholar] [PubMed]
  33. Ray WA, Chung CP, Murray KT, Hall K, Stein CM (2009) Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 360: 225-235 [CrossRef] [Google Scholar] [PubMed]
  34. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J (2010) Practice Guideline for the Treatment of Patients with Schizophrenia, 90 p
  35. Zornberg GL, Jick H (2000) Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet 356: 1219-1223 [CrossRef] [Google Scholar] [PubMed]
  36. Dayalu P, Chou KL (2008) Antipsychotic-induced extrapyramidal symptoms and their management. Expert Opinions in Pharmacotherapy 9: 1451-1462 [CrossRef] [Google Scholar] [PubMed]
  37. Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, et al. (2008) Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 193: 279-288 [CrossRef] [Google Scholar] [PubMed]
  38. Correll CU, Schenk EM (2008) Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 21: 151-156 [CrossRef] [Google Scholar] [PubMed]
  39. Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, et al. (2010) Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: A prospective cohort study. J Clin Psychiatry 71: 463-474 [CrossRef] [Google Scholar] [PubMed]
  40. Troller JN, Chen X, Sachdev PS (2009) Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 23: 477-492 [CrossRef] [Google Scholar] [PubMed]
  41. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, et al. (2009) Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents. JAMA 302: 1765-1773 [CrossRef] [Google Scholar] [PubMed]
  42. Devinsky O, Honigfeld G, Patin J (1991) Clozapine-related seizures. Neurology 41: 369-371 [CrossRef] [Google Scholar] [PubMed]
  43. Alper K, Schwartz KA, Kolts RL, Khan A (2007) Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 62: 345-354 [CrossRef] [Google Scholar] [PubMed]
  44. Roke Y, van Harten PN, Boot AM, Buitelaar JK (2009) Antipsychotic medication in children and adolescents: A descriptive review of the effects on prolactin level and associated side effects. J Child Adolesc Psychopharmacol 19: 403-414 [CrossRef] [Google Scholar] [PubMed]
  45. Crilly J (2007) The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry 18: 39-60 [CrossRef] [Google Scholar] [PubMed]
  46. de la Chapelle A, Kari C, Nurminen M, Hernberg S (1977) Clozapineinduced agranulocytosis. A genetic and epidemiologic study. Hum Genet 37: 183-194 [CrossRef] [Google Scholar] [PubMed]
  47. Honigfeld G (1996) Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis. Psychiatr Serv 47: 52-56 [CrossRef] [Google Scholar] [PubMed]
  48. Harrison-Woolrych M, Skegg K, Ashton J, Herbison P, Skegg DCG (2011) Nocturnal enuresis in patients taking clozapine, risperidone, olanzapine and quetiapine: comparative cohort study. Br J Psychiatry 199:140-144 [CrossRef] [Google Scholar] [PubMed]
  49. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, et al. (1998) A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 55: 633-641 [CrossRef] [Google Scholar] [PubMed]
  50. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL (2002) Doubleblind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159:1337-1346 [CrossRef] [Google Scholar] [PubMed]
  51. McCracken JT, McGough J, Shah B, Cronin P, Hong D, et al. (2002) Risperidone in children with autism and serious behavioral problems. N Engl J Med 347: 314-321 [CrossRef] [Google Scholar] [PubMed]
  52. Shea S, Turgay A, Carroll A, Shulz M, Orlik H, et al. (2004) Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114: e643-e641 [CrossRef] [Google Scholar] [PubMed]
  53. Gagiano C, Read S, Thorpe L, Eerdekens M, Van Hove I (2005) Shortand long-term efficacy and safety of risperidone in adults with disruptive behavior disorders. Psychopharmacology (Berl) 179: 629-636 [CrossRef] [Google Scholar] [PubMed]
  54. Hollander E, Wasserman S, Swanson EN, Chaplin W, Schapiro ML, et al. (2006) A double –blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 16: 541-548 [CrossRef] [Google Scholar] [PubMed]
  55. Pandina GJ, Bossie CA (2007) Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 37: 367-373 [CrossRef] [Google Scholar] [PubMed]
  56. Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, et al. (2009) Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 124: 1533-1540 [CrossRef] [Google Scholar] [PubMed]
  57. Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, et al. (2009) A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 48: 1110-1119 [CrossRef] [Google Scholar] [PubMed]
  58. McDougle CJ, Holmes JP, Bronson MR, Anderson GM, Volkmar FR, et al. (1997) Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study. J Am Acad Child Adolesc Psychiatry 36: 685-693 [CrossRef] [Google Scholar] [PubMed]
  59. Martin A, Koenig K, Scahill L, Bregman J (1999) Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 9: 99-107 [CrossRef] [Google Scholar] [PubMed]
  60. Friedlander R, Lazar, Klancnik J (2001) Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities. Can J Psychiatry 46: 741-745 [CrossRef] [Google Scholar] [PubMed]
  61. Malone RP, Cater J, Sheikh RM, Choudhury MS, Delaney MA (2001) Olanzapine versus haloperidol in children with autistic disorder: An open pilot study. J Am Acad Child Adolesc Psychiatry 40: 887-894 [CrossRef] [Google Scholar] [PubMed]
  62. Masi G, Cosenza A, Mucci M, Brovedani P (2001) Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 40: 1206-1214 [CrossRef] [Google Scholar] [PubMed]
  63. Kemner C, Willemsen-Swinkels SH, de Jonge M, Tuynman-Qua H, van Engeland H (2002) Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 22: 455-460 [CrossRef] [Google Scholar] [PubMed]
  64. Malone RP, Maislin G, Choudhury MS, Gifford C, Delaney MA (2002) Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry 41: 140-147 [CrossRef] [Google Scholar] [PubMed]
  65. McDougle CJ, Kem DL, Posey DJ (2002) Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 41: 921-927 [CrossRef] [Google Scholar] [PubMed]
  66. Masi G, Cosenza A, Mucci M, Brovedani P (2003) A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry 64: 1039-1047 [CrossRef] [Google Scholar] [PubMed]
  67. Gagliano A, Germano E, Pustorino G, Impallomeni C, D’Arrigo C, et al. (2004) Risperidone treatment of children with autistic disorder: Effectiveness, tolerability, and pharmacokinetic implications. J Child Adolesc Psychopharmacol 14: 39-47 [CrossRef] [Google Scholar] [PubMed]
  68. Stavrakaki C, Antochi R, Emery PC (2004) Olanzapine in the treatment of pervasive developmental disorders: a case series analysis. J Psychiatry Neurosci 29: 57-60 [Google Scholar] [PubMed]
  69. Stigler KA, Posey DJ, McDougle CJ (2004) Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol 14: 455-463 [CrossRef] [Google Scholar] [PubMed]
  70. Findling RL, McNamara NK, Gracious BL, O'Riordan MA, Reed MD, et al. (2004) Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol 14: 287-294 [CrossRef] [Google Scholar] [PubMed]
  71. Corson AH, Barkenbus JE, Posey DJ, Stigler KA, McDougle CJ (2004) A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry 65: 1531-1536 [CrossRef] [Google Scholar] [PubMed]
  72. Hardan AY, Jou RJ, Handen BL (2005) Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. J Autism Dev Disord 35: 387-391 [CrossRef] [Google Scholar] [PubMed]
  73. Rugino TA, Janvier YM (2005) Aripiprazole in children and adolescents: clinical experience. J Child Neurol 20: 603-610 [CrossRef] [Google Scholar] [PubMed]
  74. Malone RP, Delaney MA, Hyman SB, Cater JR (2007) Ziprasidone in adolescents with autism: an open-label pilot study. J Child Adolesc Psychopharmacol 17: 779-790 [CrossRef] [Google Scholar] [PubMed]
  75. Capone GT, Goyal P, Grados M, Smith B, Kammann H (2008) Risperidone use in children with down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: A naturalistic study. J Dev Behav Pediatr 29: 106-116 [CrossRef] [Google Scholar] [PubMed]
  76. Stigler KA, Diener JT, Kohn AE, Li L, Erickson CA, Posey DJ, McDougle CJ (2009) Aripiprazole in pervasive developmental disorder not otherwise specified and asperger’s disorder: A 14-week, prospective, open-label study. J Child Adolesc Psychopharmacol 19: 265-274 [CrossRef] [Google Scholar] [PubMed]
  77. Amore M, Bertelli M, Villani D, Tamborini S, Rossi M (2011) Olanzapine vs. risperidone in treating aggressive behaviours in adults with intellectual disability: a single blind study. J Intellect Disabil Res 55: 210-218 [CrossRef] [Google Scholar] [PubMed]
  78. Aman MG, McDougle CJ, Scahill L, Handen B, Arnold LE, et al. (2009) Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry 48:1143-1154 [CrossRef] [Google Scholar] [PubMed]
  79. Hellings JA, Zarcone JR, Reese RM, Valdovinos MG, Marquis JG, et al. (2006) A crossover study of risperidone in children, adolescents and adults with mental retardation. J Autism Dev Disord 36: 401-411 [CrossRef] [Google Scholar] [PubMed]
  80. Zarcone JR, Hellings JA, Crandall K, Reese RM, Marquis J, et al. (2001) Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures. Am J Ment Retard 106: 525-538 [CrossRef] [Google Scholar] [PubMed]
  81. Troost PW, Lahuis BE, Steenhuis MP, Ketelaars CE, Buitelaar JK, et al. (2005) Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry 44: 1137-1144.82 [CrossRef] [Google Scholar] [PubMed]
  82. Cohen SA, Underwood MT (1994) The use of clozapine in a mentally retarded and aggressive population. J Clin Psychiatry 55: 440-444 [Google Scholar] [PubMed]
  83. Janowsky DS, Barnhill LJ, Davis JM (2003) Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: A retrospective, open-label, naturalistic trial. J Clin Psychiatry 64: 1258-1265 [CrossRef] [Google Scholar] [PubMed]
  84. Lott RS, Kerrick JM, Cohen SA (1996) Clinical and economic aspects of risperidone in adults with mental retardation and behavioral disturbance. Psychopharmacol Bull 32: 721-729 [Google Scholar] [PubMed]
  85. Cohen SA, Ihrig K, Lott RS, Kerrick JM (1998) Risperidone for aggression and self-injurious behavior in adults with mental retardation. J Autism Dev Disord 28: 229-233 [CrossRef] [Google Scholar] [PubMed]
  86. McMurtry CM, Noel M, Chambers CT, McGrath PJ (2011) Children's fear during procedural pain: preliminary investigation of the Children's Fear Scale. Health Psychol 30: 780-788 [CrossRef] [Google Scholar] [PubMed]
  87. Frazier TW, Youngstrom EA, Haycook T, Sinoff A, Dimitriou F, et al. (2010) Effectiveness of medication combined with intensive behavioral interventions for reducing aggression in youth with autism spectrum disorder. J Child Adolesc Psychopharmacol 20: 167-177 [CrossRef] [Google Scholar] [PubMed]
  88. Durand VM (1982) A behavioral/pharmacological intervention for the treatment of severe self-injurious behavior. J Autism Dev Disord 12: 243- 251 [CrossRef] [Google Scholar] [PubMed]
  89. Lichstein KL, Schreibman L (1976) Employing electric shock with autistic children. A review of the side effects. J Autism Child Schizophr 6: 163-173. [CrossRef] [Google Scholar] [PubMed]
  90. Matson JL, Taras ME (1989) A 20 year review of punishment and alternative methods to treat problem behaviors in developmentally delayed persons. Res Dev Disabil 10: 85-104 [CrossRef] [Google Scholar] [PubMed]
  91. Mudford OC, Boundy K, Murray AD (1995) Therapeutic shock device (TSD): clinical evaluation with self-injurious behaviors. Res Dev Disabil 16: 253-267 [CrossRef] [Google Scholar] [PubMed]
  92. Duker PC, Seys DM (1996) Long-term use of electrical aversion treatment with self-injurious behavior. Res Dev Disabil 17: 293-301 [CrossRef] [Google Scholar] [PubMed]
  93. Duker PC, Seys DM (2000) A quasi-experimental study on the effect of electrical aversion on imposed mechanical restraint for severe self-injurious behavior. Res Dev Disabil 21: 235-242 [CrossRef] [Google Scholar] [PubMed]
  94. Duker PC, Van den Munckhof M (2007) Heart rate and the role of the active receiver during contingent electric shock for severe self-injurious behavior. Res Dev Disabil 28: 43-49 [CrossRef] [Google Scholar] [PubMed]
  95. Linscheid TR, Iwata BA, Ricketts RW, Williams DE, Griffin JC (1990) Clinical evaluation of the self-injurious behavior inhibiting system (SIBIS). J Appl Behav Anal 23: 53-78 [CrossRef] [Google Scholar] [PubMed]
  96. Ricketts R, Goza A, Matese M (1992) Case study: Effects of Naltrexone and SIBIS on self-injury. Behavioral Residential Treatment 7: 315-326 [CrossRef] [Google Scholar]
  97. Williams DE, Kirkpatrick-Sanchez S, Iwata BA (1993) A comparison of shock intensity in the treatment of longstanding and severe self-injurious behavior. Res Dev Disabil 14: 207-219 [CrossRef] [Google Scholar] [PubMed]
  98. Linscheid TR, Pejeau C, Cohen S, Footo-Lenz M (1994) Positive side effects in the treatment of SIB using the Self-Injurious Behavior Inhibiting System (SIBIS): Implications for operant and biochemical explanations of SIB. Res Dev Disabil 15:81-90 [CrossRef] [Google Scholar] [PubMed]
  99. Linscheid TR, Reichenbach H (2002) Multiple factors in the long-term effectiveness of contingent electric shock treatment for self-injurious behavior: a case example. Res Dev Disabil 23: 161-177 [CrossRef] [Google Scholar] [PubMed]
  100. Salvy S, Mulick JA, Butter E, Bartlett RK, Linscheid TR (2004) Contingent electric shock (SIBIS) and a conditioned punisher eliminate severe head banging in a preschool child. Behavioral Interventions 19: 59-723 [CrossRef] [Google Scholar]
  101. van Oorsouw WM, Israel ML, von Heyn RE, Duker PC (2008) Side effects of contingent shock treatment. Res Dev Disabil 29: 513-523 [CrossRef] [Google Scholar] [PubMed]
  102. Israel ML, Blenkush NA, von Heyn RE, Sands CC (2010) Seven case studies of individuals expelled from positive-only programs. Journal of Behavior Analysis of Offender and Victim Treatment and Prevention 2: 20- 36 [CrossRef] [Google Scholar]
  103. Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. Rockville, MD, U.S. Deparment of Health, Education, and Welfare. 218- 222 pp. [Google Scholar]
  104. Green VA, O'Reilly M, Itchon J, Sigafoos J (2005) Persistence of early emerging aberrant bhavior in children with developmental disabilities. Res Dev Disabil 26: 47-55 [CrossRef] [Google Scholar] [PubMed]
  105. Green VA, O'Reilly M, Itchon J, Sigafoos J (2005) Persistence of early emerging aberrant behavior in children with developmental disabilities. Res Dev Disabil 26: 47-55 [CrossRef] [Google Scholar] [PubMed]
  106. Lindsley OR (1964) Direct measurement and prosthesis of retarded behavior. Journal of Education 147:62-81. [CrossRef] [Google Scholar]
  107. Johnston JM, Pennypacker HS (1980) Strategies and tactics of human behavioral research. Hillsdale, NJ: Erlbaum
  108. Thompson T, Hackenberg TD, Schall DW (1991) Pharmacological Treatments for Behavior Problems in Developmental Disabilities. In, Treatment of Destructive Behaviors in Persons with Developmental Disabilities, Bethesda, MD: NIH Consensus Development Conference, pp. 343- 439
  109. Singh NN, Landrum TJ, Ellis CR, Donatelli LS (1993) Effects of thioridazine and visual screening on stereotypy and social behavior in individuals with mental retardation. Res Dev Disabil 14: 163-177 [CrossRef] [Google Scholar] [PubMed]
  110. May P, London EB, Zimmerman T, Thompson R, Mento T, et al. (1995) A study of the clinical outcome of patients with profound mental retardation gradually withdrawn from chronic neuroleptic medication. Ann Clin Psychiatry 7:155-160 [CrossRef] [Google Scholar] [PubMed]
  111. Mace FC, Blum NJ, Sierp BJ, Delaney BA, Mauk JE (2001) Differential response of operant self-injury to pharmacologic versus behavioral treatment. J Dev Behav Pediatr 22: 85-91 [Google Scholar] [PubMed]
  112. Janowsky DS, Barnhill LJ, Shetty M, Davis JM (2005) Minimally effective doses of conventional antipsychotic medications used to treat aggression, self-injurious and destructive behaviors in mentally retarded adults. J Clin Psychopharmacol 25: 19-25 [CrossRef] [Google Scholar] [PubMed]
  113. Miral S, Gencer O. Inal-Emiroglu FN, Baykara B, Baykara A, Dirik E (2008) Risperidone versus haloperidol in children and adolescents with AD. Eur Child Adolesc Psychiatry 17: 1-8 [CrossRef] [Google Scholar] [PubMed]
  114. Gencer O, Emiroglu FN, Miral S, Baykara B, Baykara A, et al. (2008) Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study. Eur Child Adolesc Psychiatry 17: 217-225 [CrossRef] [Google Scholar] [PubMed]
  115. Tyrer P, Oliver-Africano PC, Ahmed Z, Bouras N Cooray, S. Deb, S….. Crawford, M. (2008). Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomized controlled trial. Lancet 371: 57-63 [CrossRef] [Google Scholar] [PubMed]
  116. White TJ, Aman MG (1985) Pimozide treatment in disruptive severely retarded patients. Aust N Z J Psychiatry 19: 92-94 [CrossRef] [Google Scholar] [PubMed]
  117. Aman MG, White AJ (1988) Thioridazine dose effects with reference to stereotypic behavior in mentally retarded residents. J Autism Dev Disord 18: 355-366 [CrossRef] [Google Scholar] [PubMed]
  118. Aman MG, Teehan CJ., White AJ, Turbott SH, Vaithianathan C (1989) Haloperidol treatment with chronically medicated residents: Dose effects on clinical behavior and reinforcement contingencies. Am J Ment Retard 93:452-460 [Google Scholar] [PubMed]
  119. Perry R, Campbell M, Adams P, Lynch N, Spencer EK, et al. (1989) Long-term efficacy of haloperidol in autistic children: Continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry 28: 87-92 [CrossRef] [Google Scholar] [PubMed]
  120. Millichamp CJ, Singh NN (1987) The effects of intermittent drug therapy on stereotypy and collateral behaviors of mentally retarded persons. Res Dev Disabil 8: 213-227 [CrossRef] [Google Scholar] [PubMed]
  121. Burgio LD, Page TJ, Capriotti RM (1985) Clinical behavioral pharmacology: Methods for evaluating medications and contingency management. J Appl Behav Anal 18: 45-59 [CrossRef] [Google Scholar] [PubMed]
  122. Luiselli JK (1986) Behavior analysis of pharmacological and contingency management interventions for self-injury. J Behav Ther Exp Psychiatry 17: 275-284 [CrossRef] [Google Scholar] [PubMed]
  123. Heistad GT, Zimmermann RL, Doebler MI (1982) Long-term usefulness of thioridazine for institutionalized mentally retarded patients. Am J Ment Defic 87: 243-251 [Google Scholar] [PubMed]
  124. Perry R, Pataki C, Munoz-silva DM, Armenteros J (1997) Risperidone in Children and Adolescents with pervasive developmental disorder: Pilot trial and follow-up. J Child Adolesc Psychopharmacol 7: 167-179 [CrossRef] [Google Scholar] [PubMed]
  125. Nicolson R, Awad G, Sloman L (1998) An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry 37: 372-376 [CrossRef] [Google Scholar] [PubMed]
  126. Fido A, Al-Saad S (2008) Olanzapine in the treatment of behavioral problems associated with autism: an open-label trial in Kuwait. Med Princ Pract 17: 415-418 [CrossRef] [Google Scholar] [PubMed]
  127. Marcus RN, Owen R, Manos G, Mankoski R, Kamen L, et al. (2011) Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: Results from a 52-week, open-label study. J Child Adolesc Psychopharmacol 21: 229-236 [CrossRef] [Google Scholar] [PubMed]
  128. Dartnall NA, Holmes JP, Morgan SN, McDougle CJ (1999) Brief Report: Two-year control of behavioral symptoms with risperidone in two profoundly retarded adults with autism. J Autism Dev Disord 29: 87-91 [CrossRef] [Google Scholar] [PubMed]
  129. Crosland KA, Zarcone JR, Lindauer SE, Valdovinos MG, Zarcone TJ, et al. (2003) Use of functional analysis methodology in the evaluation of medication effects. J Autism Dev Disord 33: 271-279 [CrossRef] [Google Scholar] [PubMed]
  130. Ruedrich SL, Swales TP, Rossvanes C, Diana L Arkadiev V, et al. (2008). Atypical antipsychotic medication improves aggression but not selfinjurious behaviour, in adults with intellectual disabilities. J Intellect Disabil Res 52:132-140 [CrossRef] [Google Scholar] [PubMed]
  131. Tate BG, Baroff GS (1966) Aversive control of self-injurious behavior in a psychotic boy. Behav Res Ther 4: 281-287 [CrossRef] [Google Scholar] [PubMed]
  132. Baroff GS, Tate BG (1968) The use of aversive stimulation in the treatment of chronic self-injurious behavior. J Am Acad Child Psychiatry 7: 454-470 [CrossRef] [Google Scholar] [PubMed]
  133. Risley TR (1968) The effects and side effects of punishing the autistic behaviors of a deviant child. J Appl Behav Anal 1: 21-34 [CrossRef] [Google Scholar] [PubMed]
  134. Whaley D, Tough J (1968) Treatment of a self-injuring mongoloid with shock-induced suppression and avoidance. Michigan Mental Health Research Bulletin 2: 33-35
  135. Kushner M (1969) Faradic aversive controls in clinical practice. In: C. Nueringer & I.L. Michael (Eds.) Behavior modification in clinical psychology, 26-51 p
  136. Lovaas OI, Simmons JQ (1969) Manipulation of self-destruction in three retarded children. J Appl Behav Anal 2: 143-157 [CrossRef] [Google Scholar] [PubMed]
  137. Ludwig AM, Marx AJ, Hill PA, Browning RM (1969) The control of violent behavior through faradic shock. J Nerv Ment Dis 148: 624-637 [CrossRef] [Google Scholar] [PubMed]
  138. Kohlenberg RJ (1970) The punishment of persistent vomiting: a case study. J Appl Behav Anal 3: 241-245 [CrossRef] [Google Scholar] [PubMed]
  139. Kohlenberg RJ (1970) The punishment of persistent vomiting: a case study. J Appl Behav Anal 3: 241-245 [CrossRef] [Google Scholar] [PubMed]
  140. Bucher B, King LW (1971) Generalization of punishment effects in the deviant behavior of a psychotic child. Behavior Therapy 2: 68-77 [CrossRef] [Google Scholar]
  141. Corte HE, Wolf MM, Locke BJ (1971) A comparison of procedures for eliminating self-injurious behavior of retarded adolescents. J Appl Behav Anal 4: 201-213 [CrossRef] [Google Scholar] [PubMed]
  142. Baumeister AA, Forehand R (1972) Effects of contingent shock and verbal command on body rocking of retardates. J Clin Psychol 28: 586-590 [CrossRef] [Google Scholar] [PubMed]
  143. Tate BG (1972) Case study: Control of chronic self-injurious behavior by conditioning procedures. Behavior Therapy 3:72-83 [CrossRef] [Google Scholar]
  144. Brandsma JM, Stein LI (1973) The use of punishment as a treatment modality: a case report. J Nerv Ment Dis 156: 30-37 [CrossRef] [Google Scholar] [PubMed]
  145. Hall H, Thorne DE, Shinedling M, Sagers PS (1973) Overcoming situationspecific problems associated with typical institutional attempts to suppress self-mutilative behavior. Train Sch Bull (Vinel) 70:111-114 [Google Scholar] [PubMed]
  146. Merbaum M (1973) The modification of self-destructive behavior by a mother-therapist using aversive stimulation. Behavior Therapy 4:442-447 [CrossRef] [Google Scholar]
  147. Wright L (1973) Aversive conditioning of self-induced seizures. Behavior Therapy 4:712-713 [CrossRef] [Google Scholar]
  148. Prochaska J, Smith N, Marzilli R, Colby J, Donovan W (1974) Remotecontrol aversive stimulation in the treatment of head-banging in a retarded child. Journal of Behavior Therapy and Experimental Psychiatry 5:285-289 [CrossRef] [Google Scholar]
  149. Ramey G (1974) Use of electric shock in the classroom: The remediation of self abusive behavior in a retarded child. Behavioral Engineering 1: 4-9 [Google Scholar]
  150. Young JA, Wincze JP (1974) The effects of the reinforcement of compatible and incompatible alternative behaviors on the self-injurious and related behaviors of a profoundly retarded female adult. Behavior Therapy 5:614- 623 [Google Scholar]
  151. Ball T, Sibbach L, Jones R, Steele B, Frazier L (1975) An accelerometeractivated device to control assaultive and self-destructive behaviors in retardates. Behavior Therapy and Experimental Psychiatry 6: 223-228 [CrossRef] [Google Scholar]
  152. Romanczyk RG, Goren ER (1975) Severe self-injurious behavior: the problem of clinical control. J Consult Clin Psychol 43: 730-739 [CrossRef] [Google Scholar] [PubMed]
  153. Duker PC (1976) Remotely applied punishment versus avoidance conditioning in the treatment of self-injurious behaviors. European Journal of behavior Analysis and Modification, 3:179-184 [Google Scholar]
  154. Anderson L, Dancis J, Alpert M (1978) Behavioral contingencies and selfmutilation in Lesch-Nyhan disease. J Consult Clin Psychol 46: 529-536 [CrossRef] [Google Scholar] [PubMed]
  155. Foxx RM, Bittle RG, Faw GD (1989) A maintenance strategy for discontinuing aversive procedures: a 52-month follow-up of the treatment of aggression. Am J Ment Retard 94: 27-36 [Google Scholar] [PubMed]
  156. Dressler D, Benecke R (2005) Diagnosis and management of acute movement disorders. J Neurol 252: 1299-1306 [CrossRef] [Google Scholar] [PubMed]
  157. Dressler D, Benecke R (2005) Diagnosis and management of acute movement disorders. J Neurol 252: 1299-1306 [CrossRef] [Google Scholar] [PubMed]
  158. Caprilli S, Anastasi F, Grotto RP, Scollo Abeti M, Messeri A (2007) Interactive music as a treatment for pain and stress in children during venipuncture: a randomized prospective study. J Dev Behav Pediatr 28: 399-403 [CrossRef] [Google Scholar] [PubMed]
  159. Bruner JMR (1994 September 16) Letter to the Judge Rotenberg Center. Copy in possession of The Judge Rotenberg Center
  160. Bruner JMR, Leonard PF (1989) Electricity, Safety, and the Patient. Chicago, Illinois: Year Book Medical Publishers, INC
  161. Aman MG, Kasper W, Manos G, Mathew S, Marcus R, et al. (2010) Line- Item Analysis of the Aberrant Behavior Checklist: Results from Two Studies of Aripiprazole in the Treatment of Irritability Associated with Autistic Disorder. J Child Adolesc Psychopharmacol 20: 415-422 [CrossRef] [Google Scholar] [PubMed]
  162. Beneke M, Rasmus W (1992) "Clinical Global Impressions" (ECDEU): some critical comments. Pharmacopsychiatry 25: 171-176 [CrossRef] [Google Scholar] [PubMed]
  163. Berk M, Ng F, Dodd S, Callaly T, Campbell S, et al. (2008) The validity of the CGI severity and improvement scales as measures of clinical effectiveness suitable for routine clinical use. J Eval Clin Pract 14: 979-983 [CrossRef] [Google Scholar] [PubMed]
  164. Lemmon ME, Gregas M, Jeste SS (2011) Risperidone use in autism spectrum disorders: A retrospective review of a clinic-referred patient population. J Child Neurol 26: 428-432 [CrossRef] [Google Scholar] [PubMed]
  165. Graf S, Lindsley OR (2002) Standard Celeration Charting 2002. Graf Implements: Poland, Ohio
  166. Fountas KN, Smith JR, Lee GP (2007) Bilateral stereotactic amygdolotomy for self-mutilation disorder report and review of the literature. Stereotact Funct Neurosurg 85:121-128 [CrossRef] [Google Scholar] [PubMed]